A citation-based method for searching scientific literature

Vesna Sossi, Raúl de La Fuente-Fernández, James E Holden, Doris J Doudet, Jess McKenzie, A J Stoessl, T J Ruth. J Cereb Blood Flow Metab 2002
Times Cited: 89







List of co-cited articles
1104 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
C S Lee, A Samii, V Sossi, T J Ruth, M Schulzer, J E Holden, J Wudel, P K Pal, R de la Fuente-Fernandez, D B Calne,[...]. Ann Neurol 2000
366
38

A reversible tracer analysis approach to the study of effective dopamine turnover.
V Sossi, D J Doudet, J E Holden. J Cereb Blood Flow Metab 2001
52
46

6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
D J Doudet, G L Chan, J E Holden, E G McGeer, T A Aigner, R J Wyatt, T J Ruth. Synapse 1998
59
40


Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.
Vesna Sossi, Raúl de la Fuente-Fernández, James E Holden, Michael Schulzer, Thomas J Ruth, Jon Stoessl. J Cereb Blood Flow Metab 2004
66
34

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.
R de la Fuente-Fernández, J Q Lu, V Sossi, S Jivan, M Schulzer, J E Holden, C S Lee, T J Ruth, D B Calne, A J Stoessl. Ann Neurol 2001
148
19


Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Vesna Sossi, Raúl de la Fuente-Fernández, Michael Schulzer, Andre R Troiano, Thomas J Ruth, A Jon Stoessl. Ann Neurol 2007
93
19


Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.
C S Patlak, R G Blasberg, J D Fenstermacher. J Cereb Blood Flow Metab 1983
15

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
Raúl de la Fuente-Fernández, Vesna Sossi, Zhigao Huang, Sarah Furtado, Jian-Qiang Lu, Donald B Calne, Thomas J Ruth, A Jon Stoessl. Brain 2004
289
15

Nigrostriatal function in humans studied with positron emission tomography.
W R Martin, M R Palmer, C S Patlak, D B Calne. Ann Neurol 1989
281
14

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
H Bernheimer, W Birkmayer, O Hornykiewicz, K Jellinger, F Seitelberger. J Neurol Sci 1973
14

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Alan L Whone, Ray L Watts, A Jon Stoessl, Margaret Davis, Sven Reske, Claude Nahmias, Anthony E Lang, Olivier Rascol, Maria J Ribeiro, Philippe Remy,[...]. Ann Neurol 2003
588
14

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
John R Adams, Hinke van Netten, Michael Schulzer, Edwin Mak, Jessamyn Mckenzie, Audrey Strongosky, Vesna Sossi, Thomas J Ruth, Chong S Lee, Matthew Farrer,[...]. Brain 2005
185
14

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
J S Rakshi, T Uema, K Ito, D L Bailey, P K Morrish, J Ashburner, A Dagher, I H Jenkins, K J Friston, D J Brooks. Brain 1999
210
13

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.
B J Snow, I Tooyama, E G McGeer, T Yamada, D B Calne, H Takahashi, H Kimura. Ann Neurol 1993
271
13

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
K A Frey, R A Koeppe, M R Kilbourn, T M Vander Borght, R L Albin, S Gilman, D E Kuhl. Ann Neurol 1996
239
13

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
P K Morrish, J S Rakshi, D L Bailey, G V Sawle, D J Brooks. J Neurol Neurosurg Psychiatry 1998
368
13

Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
J E Holden, D Doudet, C J Endres, G L Chan, K S Morrison, F J Vingerhoets, B J Snow, B D Pate, V Sossi, K R Buckley,[...]. J Nucl Med 1997
46
23


Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Vesna Sossi, Raúl de la Fuente-Fernández, Michael Schulzer, John Adams, Jon Stoessl. Brain 2006
61
18

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
E Nurmi, H M Ruottinen, J Bergman, M Haaparanta, O Solin, P Sonninen, J O Rinne. Mov Disord 2001
152
11

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
Ruediger Hilker, Katherine Schweitzer, Silke Coburger, Mehran Ghaemi, Simon Weisenbach, Andreas H Jacobs, Jobst Rudolf, Karl Herholz, Wolf-Dieter Heiss. Arch Neurol 2005
189
11

FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa.
W D Brown, M D Taylor, A D Roberts, T R Oakes, M J Schueller, J E Holden, L M Malischke, O T DeJesus, R J Nickles. Neurology 1999
70
12

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
N Pavese, A H Evans, Y F Tai, G Hotton, D J Brooks, A J Lees, P Piccini. Neurology 2006
127
10

Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
Nicolaas I Bohnen, Roger L Albin, Robert A Koeppe, Kristine A Wernette, Michael R Kilbourn, Satoshi Minoshima, Kirk A Frey. J Cereb Blood Flow Metab 2006
170
10

Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
A Antonini, K L Leenders, P Vontobel, R P Maguire, J Missimer, M Psylla, I Günther. Brain 1997
173
10

Changes in network activity with the progression of Parkinson's disease.
Chaorui Huang, Chengke Tang, Andrew Feigin, Martin Lesser, Yilong Ma, Michael Pourfar, Vijay Dhawan, David Eidelberg. Brain 2007
271
10

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study.
R Nandhagopal, L Kuramoto, M Schulzer, E Mak, J Cragg, Chong S Lee, J McKenzie, S McCormick, A Samii, A Troiano,[...]. Brain 2009
149
10

Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.
Chris C Tang, Kathleen L Poston, Vijay Dhawan, David Eidelberg. J Neurosci 2010
133
10

Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
C R Freed, P E Greene, R E Breeze, W Y Tsai, W DuMouchel, R Kao, S Dillon, H Winfield, S Culver, J Q Trojanowski,[...]. N Engl J Med 2001
8



Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex.
V Kaasinen, E Nurmi, A Brück, O Eskola, J Bergman, O Solin, J O Rinne. Brain 2001
113
8

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.
K L Marek, J P Seibyl, S S Zoghbi, Y Zea-Ponce, R M Baldwin, B Fussell, D S Charney, C van Dyck, P B Hoffer, R P Innis. Neurology 1996
299
8

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
F J Vingerhoets, M Schulzer, D B Calne, B J Snow. Ann Neurol 1997
258
8

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations.
R de la Fuente-Fernández, P K Pal, F J Vingerhoets, A Kishore, M Schulzer, E K Mak, T J Ruth, B J Snow, D B Calne, A J Stoessl. J Neural Transm (Vienna) 2000
52
15

6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
H Hoshi, H Kuwabara, G Léger, P Cumming, M Guttman, A Gjedde. J Cereb Blood Flow Metab 1993
98
8

6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
J R Barrio, S C Huang, W P Melega, D C Yu, J M Hoffman, J S Schneider, N Satyamurthy, J C Mazziotta, M E Phelps. J Neurosci Res 1990
49
16

Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
Raúl de la Fuente-Fernández, Michael Schulzer, Edwin Mak, Donald B Calne, A Jon Stoessl. Brain 2004
80
10

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
E Bezard, S Dovero, C Prunier, P Ravenscroft, S Chalon, D Guilloteau, A R Crossman, B Bioulac, J M Brotchie, C E Gross. J Neurosci 2001
349
8

PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
A R Troiano, R de la Fuente-Fernandez, V Sossi, M Schulzer, E Mak, T J Ruth, A J Stoessl. Neurology 2009
72
11

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.
C Warren Olanow, Christopher G Goetz, Jeffrey H Kordower, A Jon Stoessl, Vesna Sossi, Mitchell F Brin, Kathleen M Shannon, G Michael Nauert, Daniel P Perl, James Godbold,[...]. Ann Neurol 2003
996
8

Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
Ramachandiran Nandhagopal, Lisa Kuramoto, Michael Schulzer, Edwin Mak, Jacqueline Cragg, Jess McKenzie, Siobhan McCormick, Thomas J Ruth, Vesna Sossi, Raul de la Fuente-Fernandez,[...]. Brain 2011
86
9




Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.
M J Zigmond, E D Abercrombie, T W Berger, A A Grace, E M Stricker. Trends Neurosci 1990
528
7

Dopa decarboxylase activity of the living human brain.
A Gjedde, J Reith, S Dyve, G Léger, M Guttman, M Diksic, A Evans, H Kuwabara. Proc Natl Acad Sci U S A 1991
137
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.